Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation
Effect of Amiodarone After Ischemic Ventricular Tachycardia Ablation
研究概览
详细说明
Ischemic cardiomyopathy patients have implantable cardioverter defibrillators (ICD) to prevent arrhythmic deaths. Ventricular tachycardia (VT) events with frequent ICD interventions in ischemic cardiomyopathy patients is encountered frequently. Frequents ICD interventions is associated with worse outcomes. Anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and ICD interventions that may not be curative. Ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. After ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated.
In this study we aimed to enroll ischemic cardiomyopathy patients having frequent ICD interventions despite medical treatment. VT ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. Both groups will be compared in terms of recurrence and death.
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Ankara、火鸡、06590
- 招聘中
- Turkiye Yuksek Ihtisas Training and Research Hospital
-
接触：
- Firat Ozcan, Ass. Prof, MD
- 电话号码：5327854000
- 邮箱：drfozcan@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
Ischemic cardiomyopathy patients applied with frequent ICD interventionor electrical storms and having ejection fraction below 50%. Frequent ICD defined as more than 1 ICD intervention within month. Electrical storm defined as more than 2 ICD intervention within one day.
Exclusion Criteria:
Patients with cardiomyopathies other than ischemic etiology
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Group 1
Patients underwent ablation and continued having amiodarone after the procedure
|
Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
|
|
Group 2
Patients underwent ablation and not having amiodarone after the procedure
|
Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major adverse cardiovascular events
大体时间：six months
|
Death, ICD intervetion
|
six months
|
合作者和调查者
调查人员
- 首席研究员：Firat Ozcan, MD、MD
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
Ventricular tachycardia ablation的临床试验
-
CSA Medical, Inc.终止
-
Boston Scientific Corporation招聘中